Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma

Frontiers in Immunology

Immunology

Pengju Zhang¹  Jie Li¹  Yang Pu¹  Weiwei Deng¹  Mengdi Zhang¹  Bohao Zheng¹ 

[1] State Key Laboratory of Medical Molecular Biology, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

关键词: esophageal squamous-cell carcinoma (ESCC);    immunotherapy;    prognosis;    tumor microenvironment;    immunotherapeutic responsiveness;    single-cell RNA sequencing;   

DOI  :  10.3389/fimmu.2023.1117658

 received in 2022-12-06, accepted in 2023-01-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common and lethal malignant diseases. Immunotherapy has been widely studied and has exhibited potential in ESCC treatment. However, there are only a portion of ESCC patients have benefited from immunotherapy. We herein identified immunotherapeutic response-related signatures (IRRS) and evaluated their performance in ESCC prognosis and immunotherapeutic responsiveness.MethodsWe constructed an IRRS using the gene expression data of 274 ESCC patients based on y -30significantly differentially expressed genes, which were compared responders and non-responders from various patient cohorts treated with immunotherapy. Survival analysis was performed in both the GSE53625 and TCGA-ESCC cohorts. We also explored the differences in the tumor microenvironment between the high-IRRS and low-IRRS score groups using single-cell data as a reference. Three immunotherapy cohorts were used to verify the value of the IRRS in predicting immunotherapy response.ResultsTwelve immunotherapy-related genes were selected to construct a signature score and were validated as independent prognostic predictors for patients with ESCC. Patients with high IRRS scores exhibited an immunosuppressive phenotype. Therefore, patients with low IRRS scores may benefit from immunotherapy.ConclusionsIRRS score is a biomarker for immunotherapy response and prognosis of ESCC.

【 授权许可】

Unknown   
Copyright © 2023 Zheng, Li, Zhang, Zhang, Deng and Pu